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Abstract
Purpose The use of adjuvant radiotherapy (RT) in the management of ductal carcinoma in situ (DCIS) is increasing. Left-
sided breast irradiation may involve exposure of the heart to ionising radiation, increasing the risk of ischemic heart disease 
(IHD). We examined the incidence of IHD in a population-based cohort of women with DCIS.
Methods The Breast Cancer DataBase Sweden (BCBase) cohort includes women registered with invasive and in situ breast 
cancers 1992–2012 and age-matched women without a history of breast cancer. In this analysis, 6270 women with DCIS and 
a comparison cohort of 31,257 women were included. Through linkage with population-based registers, data on comorbid-
ity, socioeconomic status and incidence of IHD was obtained. Hazard ratios (HR) for IHD with 95% confidence intervals 
(CI) were analysed.
Results Median follow-up time was 8.8 years. The risk of IHD was not increased for women with DCIS versus women in 
the comparison cohort (HR 0.93; 95% CI 0.82–1.06), after treatment with radiotherapy versus surgery alone (HR 0.77; 95% 
CI 0.60–0.98) or when analysing RT by laterality (HR 0.85; 95% CI 0.53–1.37 for left-sided versus right-sided RT).
Conclusions The risk of IHD was lower for women with DCIS allocated to RT compared to non-irradiated women and to 
the comparison cohort, probably due to patient selection. Comparison of RT by laterality did not show any over-risk for 
irradiation of the left breast.
Keywords Ductal carcinoma in situ · Radiotherapy · Ischemic heart disease
 * C. Wadsten 
 charlotta.wadsten@rvn.se
1 Department of Surgery and Perioperative Sciences, Umeå 
University, Umeå, Sweden
2 Department of Surgical Sciences, Uppsala University, 
Uppsala, Sweden
3 Department of Surgery, Sundsvall Hospital, Sundsvall, 
Sweden
4 Department of Oncology, Sundsvall Hospital, Sundsvall, 
Sweden
5 Regional Cancer Center, Uppsala University/Uppsala 
University Hospital, Uppsala, Sweden
6 Faculty of Life Sciences & Medicine, Section of Cancer 
Epidemiology & Population Health, King’s College, London, 
UK
7 Department of Immunology, Genetics and Pathology, Section 
of Experimental and Clinical Oncology, University Hospital, 
Uppsala University, Uppsala, Sweden
8 Department of Oncology, Gävle Hospital, Gävle, Sweden
9 Department of Oncology, Visby Hospital, Visby, Sweden
10 Department of Oncology, Örebro University Hospital, 
Örebro, Sweden
11 Department of Oncology, Helsinki University Hospital, 
Helsinki, Finland
12 Department of Molecular Medicine and Surgery, Karolinska 
Institute, Stockholm, Sweden
13 Department of Breast and Endocrine Surgery, Karolinska 
University Hospital, Stockholm, Sweden
96 Breast Cancer Research and Treatment (2018) 171:95–101
1 3
Introduction
The use of adjuvant radiotherapy (RT) in the management of 
ductal carcinoma in situ (DCIS) has increased substantially 
over the last decades [1–5]. Four randomised trials have dem-
onstrated that the addition of postoperative RT after breast 
conserving surgery (BCS) reduces ipsilateral breast events 
by half compared to surgery alone, but survival benefits 
remain uncertain [6–9]. In fact, in an overview of these tri-
als by the Early Breast Cancer Trialists’ Collaboration Group 
(EBCTCG), overall mortality and mortality from heart disease 
was slightly, although not statistically significant, higher in 
women allocated to RT [10].
Heart exposure to ionising radiation is associated with an 
increased risk of subsequent cardiovascular disease [11–15]. 
Modern radiation techniques have likely reduced the risk as the 
radiation dose to the heart from tangential RT has decreased 
considerably over the last 40 years [16]. The mean heart dose 
in left tangential RT has been estimated to be 13.3 Gy in the 
1970s compared to 2.3 Gy in 2006 [17]. The anterior part of 
the heart may however still receive high doses [16] and studies 
imply an increased incidence of ischemic heart disease (IHD) 
after left-sided RT compared to right-sided RT, even with 
modern RT technique [13, 15, 18]. The causal effect of RT on 
heart disease appears to be mediated by radiation damage to 
the coronary arteries, in particular the left anterior descend-
ing artery, that leads to stenosis and myocardial ischemia [15, 
19, 20].
Whereas women with invasive BC also may encounter car-
diotoxic effects of systemic treatments, potentially increasing 
the risks, treatment for DCIS characteristically only involves 
surgery and RT. A few studies have examined radiation-related 
cardiovascular hazards in DCIS [10, 21–25]. In a recent pub-
lication, left-sided RT was found to be an independent risk 
factor for increased cardiac mortality from 1973 to 1982, but 
not after 1982 [24]. Cardiovascular morbidity was, however, 
not investigated. The only two studies examining both cardio-
vascular morbidity and mortality related to DCIS treatment did 
not show any excess incidence of heart disease [22, 23]. Still, 
these results need to be confirmed and it has been postulated 
that women with pre-existing cardiovascular risk factors may 
be more vulnerable to radiation exposure [14]. The aim of this 
study was to examine the risk of IHD in a large population-
based cohort of women with DCIS given modern RT and a 
comparison cohort of age-matched women without a history 
of breast cancer (BC), adjusting for potential confounders of 
cardiac disease such as comorbidity and socioeconomic status.
Patients and methods
BCBase
In Sweden, regional registration of BC was started in the 
late 1970s to enable epidemiological surveillance of inci-
dence, tumour characteristics, management and outcome. 
The registers in three of Sweden’s six health care regions 
have been merged, creating BCBase. These three regions 
altogether cover a source population of 5.2 million, repre-
senting about 50% of Sweden’s total population. All new 
invasive and in situ breast cancers diagnosed between 1992 
and 2012 are included in the database. For the present 
study, the analyses included only women registered with 
DCIS. To this, a comparison cohort of women without 
BC has been added in a ratio of 5:1. Eligible for inclusion 
were women free of BC at the end of the year of diagnosis 
of the index case and born in the same year. Using the 
method of incidence density sampling, the women in the 
comparison cohort may have been selected for more than 
one case and were also allowed to become a case after 
the date of diagnosis of the index case. Using the unique 
personal identity number assigned to each Swedish resi-
dent, the database has been linked to a number of registers 
withheld by the National Board of Health and Welfare. 
The National Patient Register (NPR) has records of all 
hospital discharges in Sweden since 1987 and contains 
data on main diagnosis and up to eight secondary diag-
noses. The register has been validated and is estimated to 
capture about 99% of all hospitalisations [26]. The NPR 
also contains hospital-based outpatient care since 2001. 
Classification of comorbidity was performed according to 
the Charlson Comorbidity Index (CCI) using three comor-
bidity levels: 0 (no comorbidity), 1 (mild) and 2 (severe 
comorbidity) [27].
The Longitudinal Integration Database for Health Insur-
ance and Labour Market Studies is an annually updated 
register integrating data from the labour market, the edu-
cational and social sectors. This register includes data on 
various socioeconomic variables for all residents in Swe-
den, such as marital status, income, place of employment 
(county, municipality) and highest level of education [28].
Statistics
IHD was defined by the International Classification of Dis-
ease (ICD) 9th edition codes 410-414 or ICD-10 codes 
I20-I25. Hazard ratios for risk of IHD were estimated by 
Cox proportional hazards regression analysis. Only events 
requiring a hospital admission were captured and only the 
first event recognised for each subject. Time at risk started 
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at DCIS diagnosis and ended at date of IHD event, date 
of invasive breast cancer event in either the ipsilateral or 
the contralateral breast, death or end of the year of 2013, 
whichever came first. Risk of IHD was investigated by 
comparing women with DCIS to women in the compari-
son cohort, women with DCIS treated with surgery and 
RT to those having surgery alone and women receiving 
left-sided RT to those with right-sided RT. Risk estimates 
were adjusted for previous cardiovascular events, CCI and 
educational level. The CCI score was modified by remov-
ing IHD in order to avoid duplicate adjustment for this 
covariate. Cumulative incidence of IHD was calculated 
by the Kaplan–Meier method. Analyses were performed 
using the statistical software R [29].
Table 1  Characteristics of women with DCIS and women in the comparison cohort included in BCBase between 1992 and 2012
DCIS ductal carcinoma in situ, SD standard deviation, CCI Charlson comorbidity index, IHD ischemic heart disease, Yr year
a 53 women had bilateral DCIS or unknown laterality
Women with DCIS (%)a Right-sided DCIS (%) Left-sided DCIS (%) Comparison cohort (%)
No. of patients 6270 (100.0) 2978 (47.7%) 3239 (51.7) 31,257
Follow-up time years (SD) 8.8 (5.7) 8.8 (5.6) 8.8 (5.6) 8.8 (5.6)
Health care region
 Stockholm 2557 (40.8) 1207 (40.5) 1348 (41.6) 12,737 (40.7)
 Uppsala/Örebro 2628 (41.9) 1255 (42.1) 1323 (40.8) 13,124 (42.0)
 Northern region 1085 (17.3) 516 (17.3) 568 (17.5) 5396 (17.3)
Year of inclusion
 1992–1997 1387 (22.1) 614 (20.6) 720 (22.2) 6398 (20.5)
 1998–2002 1414 (22.5) 684 (23.0) 730 (22.5) 6760 (21.6)
 2003–2007 1522 (24.3) 771 (25.9) 751 (23.2) 7853 (25.1)
 2008–2012 1947 (31.1) 909 (30.5) 1038 (32.0) 10,246 (32.8)
Age at diagnosis (years)
 < 45 686 (10.9) 342 (11.5) 340 (10.5) 3310 (10.6)
 45–54 1891 (30.2) 880 (29.6) 995 (30.7) 9123 (29.2)
 55–64 1861 (29.7) 901 (30.3) 938 (29.0) 9400 (30.1)
 65–74 1388 (22.1) 648 (21.8) 732 (22.6) 7118 (22.8)
 75–84 366 (5.8) 173 (5.8) 190 (5.9) 1917 (6.1)
 85+ 78 (1.2) 34 (1.1) 44 (1.4) 389 (1.2)
Marital status
 Married 3525 (56.2) 1657 (55.6) 1831 (56.5) 17,143 (54.8)
 Not married 2745 (43.8) 1321 (44.4) 1409 (43.5) 14,114 (45.2)
Highest educational level
 Low 1580 (25.2) 755 (25.4) 800 (24.7) 8889 (28.4)
 Middle 2539 (40.5) 1202 (40.4) 1317 (40.7) 13,006 (41.6)
 High 2061 (32.9) 979 (32.9) 1075 (33.2) 8768 (28.1)
 Missing 90 (1.4) 42 (1.4) 47 (1.5) 54 (1.9)
CCI
 0 5637 (89.9) 2656 (89.2) 2932 (90.5) 27,736 (88.7)
 1 343 (5.4) 178 (6.0) 164 (5.1) 1959 (6.3)
 2 195 (3.1) 93 (3.1) 99 (3.1) 1024 (3.3)
 3+ 95 (1.5) 51 (1.7) 44 (1.4) 538 (1.7)
Previous IHD events
 0 6102 (97.3) 2901 (97.4) 3148 (97.2) 30,308 (97.0)
 1 105 (1.7) 52 (1.7) 53 (1.6) 583 (1.9)
 2+ 63 (1.0) 25 (0.8) 38 (1.2) 366 (1.2)
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Results
The study cohort consisted of 2978 women with right-
sided DCIS and 3239 with left-sided DCIS, shown in 
Table 1. To this, 31,527 women without a history of either 
invasive or in situ breast cancer were added. Mean age at 
inclusion was 58.5 years and mean follow-up time was 
8.8 years. The distributions of age at diagnosis and cal-
endar period of diagnosis were similar for all three health 
care regions. Women with DCIS had a higher level of edu-
cation compared to the women in the comparison cohort 
(32.9 vs. 28.1% in the highest level of education category) 
and they were generally healthier (89.9 vs. 88.7% with no 
comorbidity according to CCI score). Very few women 
in the DCIS group and the comparison cohort had a his-
tory of previous IHD events (2.7 and 3.1%, respectively). 
Of the women with DCIS, 38.9% received adjuvant RT 
(Table 2). Less than three per cent received adjuvant endo-
crine therapy which was expected as this is not recom-
mended in Swedish treatment guidelines (not shown in 
table). Patient characteristics and treatment did not differ 
significantly between right- and left-sided DCIS.
Risk of IHD for women with DCIS
There were a total of 269 IHD events among women with 
DCIS and 1450 IHD events in the comparison cohort 
(Table 3). The risk of IHD was not increased for women 
with DCIS versus women in the comparison cohort (unad-
justed HR 0.93; 95% CI 0.82–1.06 and adjusted HR 0.96; 
95% CI 0.85–1.10). In the comparison of IHD risk in rela-
tion to treatment of DCIS (radiotherapy versus surgery 
alone) and using the comparison cohort as reference, the 
risk was lower for women receiving RT (HR 0.77; 95% CI 
Table 2  Tumour and treatment characteristics of women with DCIS
DCIS ductal carcinoma in situ, No. numbers, BCS breast conserving 
surgery, RT radiotherapy
53 women had bilateral or unknown laterality
a 11 women had bilateral or unknown laterality
b 42 women had bilateral or unknown laterality
DCIS all DCIS right DCIS left
No. of patients 6270 2978 3239
Detection mode
 Screening 2870 (45.8) 1361 (45.7) 1475 (45.5)
 Non-screening 445 (7.1) 196 (6.6) 249 (7.7)
 Missing 2955 (47.1) 1421 (47.7) 1515 (46.8)
Tumour size (mm)
 0–5 707 (11.3) 342 (11.5) 358 (11.0)
 6–10 977 (15.6) 480 (16.1) 492 (15.2)
 11–20 1218 (19.4) 580 (19.5) 629 (19.4)
 21–50 1375 (21.9) 640 (21.5) 722 (22.3)
 > 50 421 (6.7) 203 (6.8) 216 (6.7)
 Missing 1572 (25.1) 733 (24.6) 822 (25.4)
Surgical treatment
 No surgery 29 (0.5) 14 (0.5) 15 (0.5)
 BCS 4270 (68.1) 2066 (69.4) 2167 (66.9)
 Mastectomy 1858 (29.6) 860 (28.9) 982 (30.3)
 Missing 114 (1.8) 38 (1.3) 75 (2.3)
Radiotherapy
 RT 2441 (38.9)a 1188 (39.9) 1242 (38.3)
 No RT 3829 (61.1)b 1790 (60.1) 1997 (61.7)
 BCS only 2178 (34.7) 1034 (34.7) 1118 (34.5)
 BCS + RT 2092 (33.4) 1032 (34.7) 1049 (32.4)
 Mastectomy 1564 (24.9) 722 (24.2) 826 (25.5)
 Mastectomy + RT 294 (4.7) 138 (4.6) 156 (4.8)
 Missing 142 (2.3) 52 (1.7) 90 (2.8)
Table 3  Hazard ratio of IHD 
with 95% confidence interval 
in women irradiated or not for 
DCIS versus women without a 
history of DCIS
IHD ischemic heart disease, DCIS ductal carcinoma in situ, No. number, HR hazard ratio, CI confidence 
interval, Ref reference, RT radiotherapy, CCI Charlson comorbidity index
a Adjusted for educational level, CCI and previous ischemic heart disease
b 5 events in women with bilateral DCIS or unknown laterality
No. of events HR CI Adjusted  HRa CI
No DCIS 1450 1.0 (ref) 1.0 (ref)
DCIS 269 0.93 0.82–1.06 0.96 0.85–1.10
DCIS right 129b 0.97 0.81–1.16 0.99 0.83–1.19
DCIS left 135b 0.92 0.77–1.10 0.95 0.80–1.13
No DCIS 1450 1.0 (ref) 1.0 (ref)
DCIS no RT 201 1.01 0.87–1.17 1.04 0.90–1.21
DCIS RT 68 0.77 0.60–0.98 0.79 0.62–1.01
DCIS RT right 36 0.84 0.60–1.16 0.86 0.62–1.20
DCIS RT left 32 0.72 0.51–1.02 0.74 0.52–1.06
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0.60–0.98) and at a very similar level after adjusting for 
CCI and educational level (HR 0.79; 95% CI 0.62–1.01).
Risk of IHD for women with DCIS by laterality
A comparison by laterality showed no increased risk of IHD 
from RT to the left breast (HR 0.85; 95% CI 0.53–1.37), not 
when comparing all women with DCIS, nor when comparing 
different types of surgery (Table 4). These results were not 
altered after adjusting for CCI and educational level (data 
not shown). The cumulative probability of IHD in women 
treated with adjuvant RT or surgery alone versus women 
without history of DCIS is visualised by a Kaplan–Meier 
analysis. Up to 16 years after treatment, the incidence of 
IHD for women with DCIS, whether irradiated or not, did 
not exceed that for the women in the comparison cohort 
(Fig. 1).
Discussion
In the present study, the incidence of IHD was not elevated 
for women with DCIS allocated to surgery and RT com-
pared to surgery alone or to a comparison cohort of women 
without a history of BC. Adjustment for comorbidity and 
socioeconomic status did not alter the results. Furthermore, 
there was no statistically significant difference in IHD risk 
when comparing RT by laterality.
The finding that women with BC are healthier compared 
to the background female population is in concordance 
with other reports [18, 21, 23, 25]. Several explanations to 
this have been proposed. DCIS is largely detected through 
screening. A higher educational and socioeconomic status is 
thought to lead to a healthier lifestyle in general and women 
with a high educational level are more adherent to screen-
ing [30]. Women participating in screening are also more 
prone to use hormonal replacement therapy, and it has been 
hypothesised from observational studies that the intake of 
exogenous oestrogen may be protective against coronary 
heart disease [21, 31, 32]. Some risk factors for BC are sup-
posedly protective of cardiovascular disease, for example, 
late menopause yielding a prolonged exposure of endoge-
nous oestrogen. Results provided by more recent randomised 
trials have challenged these hypotheses though and suggest 
that oestrogen use does not confer any cardiac protection, 
rather it may even increase the risk [33]. Another hypoth-
esis is that BC survivors tend to seek medical care more 
frequently [22], which can modulate their risk of coronary 
events.
The awareness of radiation-induced heart disease and 
the advent of new RT techniques have led to a substantial 
improvement in dose estimations to targets with reduced 
radiation exposure to the heart. Haque et al. compared car-
diac mortality after RT between left- and right-sided DCIS 
and found no significant excess risk for women treated after 
1982 [24]. Uncertainties about the duration of risk remain, 
as radiation-related mortality risks have been shown to be 
larger after 10–20 years after exposure than within the first 
decade [11, 12, 24, 34]. The only study that has shown a 
slight, although not statistically significant, elevated car-
diac mortality in women receiving adjuvant RT in DCIS 
is the EBCTCG overview [10]. The overview includes ran-
domised clinical trials, whereas in population-based studies, 
selection-bias needs to be considered, and accordingly risks 
Table 4  Hazard ratio of IHD with 95% confidence interval in women 
with DCIS by laterality, stratified for surgical treatment and adjuvant 
RT
IHD ischemic heart disease, DCIS ductal carcinoma in  situ, No. 
number, HR hazard ratio, CI confidence interval, Ref reference, BCS 
breast conserving surgery, RT radiotherapy
No. of events HR CI
All
 DCIS right 129 1.0 (ref) 0.74–1.20
 DCIS left 135 0.95
No RT
 DCIS right 93 1.0 (ref) 0.73–1.29
 DCIS left 103 0.97
RT
 DCIS right 36 1.0 (ref) 0.53–1.37
 DCIS left 32 0.85
BCS only
 DCIS right 63 1.0 (ref) 0.65–1.30
 DCIS left 63 0.92
BCS + RT
 DCIS right 30 1.0 (ref) 0.55–1.55
 DCIS left 28 0.92
Mastectomy
 DCIS right 33 1.0 (ref) 0.67–1.68
 DCIS left 41 1.06












No DCIS 31257 28165 23197 18870 15219 11887 9072 6473 4332
No RT 3787 3460 2925 2422 2017 1628 1285 954 634
Left RT 1242 1105 856 655 511 375 267 164 111
Right RT 1188 1041 843 655 476 343 231 159 102
IHD= ischemic heart disease, RT= Radiotherapy, DCIS= Ductal carcinoma in situ
Fig. 1  Cumulative incidence of IHD in women treated with adjuvant 
RT or surgery alone versus women without history of DCIS
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may be underestimated. Comparison between left-sided and 
right-sided RT has therefore been the most accurate way to 
evaluate the cardiovascular risk [13, 35] .
The present study did not evaluate radiation-related 
cardiac mortality, but excess morbidity and more specifi-
cally increased IHD. Darby et al showed that the increase 
of IHD begins within the first 5 years of exposure [14]. No 
excess incidence of IHD over time in women irradiated for 
DCIS compared to surgery alone was found in the present 
study. Of the two studies specifically assessing the cardiac 
morbidity risk after treatment for DCIS, the first was rather 
small including only 129 patients [22]. The largest study, 
by Boekel et al, investigated both cardiovascular morbid-
ity and mortality in 10,468 women with DCIS compared to 
the Dutch general population [23]. No excess risk of either 
cardiac morbidity or mortality was found and no difference 
in a comparison between left-sided and right-sided RT after 
a mean follow-up of 8 years, which is in line with our results 
[23]. Previous cardiovascular events were accounted for, but 
information on other cardiovascular risk factors were miss-
ing. In the present study, the registers included in BCBase 
allows for adjustment for concomitant comorbidity such as 
other cardiovascular diseases, pulmonary diseases and dia-
betes. We had no information on smoking, but could adjust 
the risk estimates by educational level which is highly cor-
related to smoking [36].
This study has several limitations. The number of events 
were limited leading to a lack of power to detect small or 
modest differences in morbidity due to IHD. Moreover, it 
may be that the median follow-up time of 8 years is too short 
to detect an excess cardiac morbidity. In a meta-analyses 
of long-term risks of coronary heart disease after RT, the 
risk increase started within the first 5 years and continued 
into the third decade after RT [15]. The highest relative risk 
occurred between 10 and 14 years after the diagnosis of 
BC. Another limitation is that as with all register studies, 
some misclassifications may be present. A validation of the 
BC register revealed that 7% of the women with registered 
DCIS actually had an invasive breast cancer [5]. However, 
there is no reason to believe that this would differ by lateral-
ity or that this low number would influence overall results. 
Finally, we had no information on individual radiation doses. 
National guidelines recommended RT by tangential field to 
the conserved breast in fractions of 2 Gy up to 50 Gy dur-
ing 5 weeks. In a validation study, the accuracy of reported 
surgical and adjuvant treatment in the register was very high 
[5].
The strengths of the study include the population-based 
setting and the opportunity to make comparisons with 
women without DCIS from the same geographical area and 
of the same age distribution with available information on 
comorbidity and educational level. This should minimise 
bias of environmental risk factors for cardiovascular disease. 
The review and validation of the NPR showed a very high 
overall coverage and high accuracy of the diagnoses of myo-
cardial infarction and angina pectoris [26]. Studying women 
with DCIS avoids the issue of systemic treatments that may 
alter the risk of cardiac morbidity, such as endocrine treat-
ment, chemotherapy and HER-2 antibodies.
Improvements in BC survival have made it increasingly 
important to consider long-term adverse effects from adju-
vant treatments. This is of particular importance for women 
with DCIS since adjuvant RT after BCS has not, as of yet, 
been shown to affect survival. The results of the present 
study are reassuring in that adjuvant RT with modern RT 
technique to the conserved breast after surgery for DCIS did 
not show any increase of IHD in the first 8 years of follow-
up. Nevertheless, the use of RT in DCIS management is 
increasing. Even small increases in risk of IHD are thus of 
importance and longer follow-up of these women may be 
warranted.
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